They found this combination treatment suppressed self-renewal genes and AR target genes in PCa cells that had SOCS3 overexpression, but the AR target genes were induced in PCa cells with SOCS3 knocked out, suggesting that uncontrolled IL6/JAK/STAT3 transactivation of androgen signaling conferred enzalutamide resistance. This evidence concerns the gene AR and posterior cortical atrophy.